PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

Onkourologiâ. 2014;9(4):71-74 DOI 10.17650/1726-9776-2013-9-4-71-74

 

Journal Homepage

Journal Title: Onkourologiâ

ISSN: 1726-9776 (Print); 1996-1812 (Online)

Publisher: ABV-press

Society/Institution: Russian Cancer Urology Society

LCC Subject Category: Medicine

Country of publisher: Russian Federation

Language of fulltext: Russian

Full-text formats available: PDF

 

AUTHORS

I. A. Korneyev (Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation)
I. A. Aboyan (Zdorovye (Health) Clinical Diagnostic Center, Nizhny Novgorod)
B. Ya. Alekseev (P.A. Herzen Moscow Oncology Research Institute, Moscow)
O. I. Apolikhin (Research Institute of Urology, Ministry of Health of the Russian Federation, Moscow)
B. K. Komyakov (I.I. Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation, Saint Petersburg)
V. B. Matveev (N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow)
M. Colombel (Hôpital Edouard Herriot, Lyon)
A. Heidenreich (Universitätsklinikum der RWTH Aachen, Aachen)
L. Martínez-Piñeiro (Hospital Infanta Sofia, Madrid)
M. Babjuk (Urologická klinika FN Motol, Prague)
C. Surcel (Fundeni Clinical Institute, Bucharest)
P. Yakovlev (Kiev Municipal Oncology Hospital, Kiev)
R. Colombo (University Vita Salute San Raffaele Hospital, Milan)
P. Radziszewski (Medical University Warsaw, Warsaw)
F. Witjes (UMC St. Radboud, Nijmegen)
P. Mulders (EAU Research Foundation, Arnhem)
R. Schipper (EAU Research Foundation, Arnhem)
W. Witjes (EAU Research Foundation, Arnhem)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 10 weeks

 

Abstract | Full Text

The paper gives an overview of peri-operative chemotherapy in patients with muscle-invasive bladder cancer (MIBC) as insufficient option, demonstrates a clinical need for the development of more efficacious and safe treatment and introduces a MAGNOLIA study proposed by the European Association of Urology Research Fund in a concept of MIBC immunotherapy. The MAGNOLIA trial conducted in 56 research centers of 10 countries assesses whether adjuvant immunotherapy with recMAGE-A3+AS15 vaccine is safe and effective and improves outcome of patients with MAGE-A3 positive MIBC after cystectomy. 60 of 273 patients have been enrolled. The trial has to be continued to elaborate a general peri-operative treatment strategy for MIBC.